alexa Optimizing Treatment Outcomes for Ocular Mucous Membrane Pemphigoid
ISSN: 2155-9570

Journal of Clinical & Experimental Ophthalmology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Optimizing Treatment Outcomes for Ocular Mucous Membrane Pemphigoid

Ryan C Teeple*, Linda Hynan and H. Dwight Cavanagh
Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX, USA
Corresponding Author : Ryan C Teeple
Department of Ophthalmology
University of Texas Southwestern Medical Center
Dallas, TX, USA
E-mail: [email protected]
Received January 15, 2013; Accepted February 01, 2013; Published February 08, 2013
Citation: Teeple RC, Hynan L, Cavanagh HD (2013) Optimizing Treatment Outcomes for Ocular Mucous Membrane Pemphigoid. J Clinic Experiment Ophthalmol S2:005. doi:10.4172/2155-9570-S2-005
Copyright: © 2013 Teeple RC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Abstract

Purpose: To evaluate the change in best corrected visual acuity over time for patients with ocular mucous membrane pemphigoid (MMP) and to compare the effectiveness of various immunosuppressive treatments in preserving vision.

Design: Retrospective chart review. Outcome measures: The principal outcome measures assessed were: improvement in vision, no change in vision or a decrease in vision.

Methods: All patients diagnosed with ocular cicatricial pemphigoid or mucous membrane pemphigoid at UT Southwestern Medical Center in Dallas, Texas from 2003 to 2012 were identified and their charts reviewed.

Results: 29 patients and 57 eyes were included in the study. 22 of the patients had positive biopsies. The average age of the patients was 67 years old. The average follow-up was 49 months (range 6–143 months). More than half (15 of 29 patients) required a change in therapy and one patient had their treatment changed seven times. When used as first drug therapy, the percent of eyes that had either no change or an actual improvement in vision over the course of that treatment was 83% (10 of 12 eyes) for Mycophenolate, 69% (22 of 32 eyes) for Dapsone, and 60% (6 of 10 eyes) for Cyclophosphamide. When second drug therapy was necessary, the percent of eyes that had either no change or an improvement in vision over the course of that treatment was 75% (3 of 4 eyes) for Rituximab, 64% (9 of 14 eyes) for Azathioprine, 50% (4 of 8 eyes) for Mycophenolate, and 25% (1 of 4 eyes) for Dapsone. Looking at all outcomes without regard to the stage of treatment, 90% of eyes (9 of 10) treated with Rituximab had either no change or an improvement in vision over the course of their treatment.

Conclusions: MMP is a blinding disease which can respond to aggressive and compliant long-term treatment. Newer therapies show promise; in this series Rituximab was found to provide the best results in preserving vision.

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords